<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20147" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cryoglobulinemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhandari</surname>
            <given-names>Jenish</given-names>
          </name>
          <aff>Punjab Medical College/University of Health Scienes</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awais</surname>
            <given-names>Mashal</given-names>
          </name>
          <aff>University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jenish Bhandari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mashal Awais declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20147.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cryoglobulinemia is a rare medical condition characterized by the presence of abnormal proteins called cryoglobulins in the blood, which precipitate or clump together at low temperatures. These cryoglobulins, composed of immunoglobulins and sometimes complement components, deposit in small- to medium-sized blood vessels throughout the body, causing endothelial injury and end-organ damage.&#x000a0;Cryoglobulins can cause a range of symptoms, including joint pain, skin rashes, and kidney problems, due to their tendency to obstruct blood vessels and trigger inflammatory reactions.</p>
        <p>Often associated with underlying diseases such as hepatitis C, autoimmune disorders, or certain cancers, cryoglobulinemia poses a diagnostic and therapeutic challenge due to its varied clinical manifestations. Treatment targets both the cryoglobulins and the underlying conditions, with options including pharmacotherapy, plasmapheresis, and management of associated diseases.&#x000a0;Diagnosis involves measuring cryoglobulin levels along with low C4 complement levels. Treatment varies based on the severity and nature of the underlying disorder, with mixed cryoglobulinemia typically treated with steroids and rituximab.&#x000a0;This activity focuses on the pathophysiology, clinical manifestations, diagnostic criteria, and management strategies of cryoglobulinemia. This activity also explores current treatment options for cryoglobulinemia, including pharmacological therapies, plasmapheresis, and management of associated conditions.&#x000a0;This activity highlights the collaborative role of the interprofessional healthcare team in improving patient care and outcomes for individuals with cryoglobulinemia by providing an in-depth understanding of the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical manifestations and laboratory findings suggestive of cryoglobulinemia.</p></list-item><list-item><p>Screen patients with suspected cryoglobulinemia for underlying conditions such as hepatitis C, autoimmune disorders, and malignancies.</p></list-item><list-item><p>Select the most suitable treatment options for cryoglobulinemia&#x000a0;based on individual patient factors and treatment goals.</p></list-item><list-item><p>Collaborate with interprofessional healthcare teams, including specialists in rheumatology, nephrology, and infectious diseases, to optimize patient care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20147&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20147">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20147.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cryoglobulins are proteins that precipitate from an individual's serum or plasma at temperatures lower than 37 &#x000b0;C. These cryoglobulins can be a mixture of immunoglobulins (Igs) and complement components or immunoglobulins alone.<xref ref-type="bibr" rid="article-20147.r1">[1]</xref>&#x000a0;They deposit in small- to medium-sized blood vessels throughout the body, causing endothelial injury and end-organ damage known as cryoglobulinemia. Diagnosis of this entity should be suspected in patients presenting with skin ulcers, arthralgia, glomerulonephritis, neuropathy, and purpura.</p>
        <p>
<bold>Types of&#x000a0;Cryoglobulinemia</bold>
</p>
        <p>The Brouet criteria classify cryoglobulinemia&#x000a0;into&#x000a0;3 subgroups based on their immunoglobulin composition.<xref ref-type="bibr" rid="article-20147.r2">[2]</xref></p>
        <p><bold>Type I:&#x000a0;</bold>Type I cryoglobulinemia has monoclonal immunoglobulins, typically IgG or IgM, and develops in the setting of lymphoproliferative or hematologic disorders of B-cell lineage, such as multiple myeloma, Waldenstr&#x000f6;m macroglobulinemia, chronic lymphocytic leukemia, or protein-secreting monoclonal gammopathies such as monoclonal gammopathy of undetermined significance (MGUS).</p>
        <p><bold>Type II:&#x000a0;</bold>Types II and III constitute mixed cryoglobulinemia, characterized by polyclonal immunoglobulins associated with autoimmune diseases, malignancy, or infections, notably hepatitis C virus (HCV) infection.<xref ref-type="bibr" rid="article-20147.r3">[3]</xref>&#x000a0;Their constituent immunoglobulin is not a single monoclonal immunoglobulin.</p>
        <p>In type II cryoglobulinemia, cryoglobulins are composed of a mixture of monoclonal IgM (or IgG or IgA) with rheumatoid factor (RF) activity, along with polyclonal immunoglobulin.</p>
        <p>Type II cryoglobulinemia is often associated with the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>HCV infection, which is the most common causative factor of cryoglobulinemic vasculitis and mixed cryoglobulinemia.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Vaccines.</p>
          </list-item>
          <list-item>
            <p>Hepatitis B virus (HBV) infection.</p>
          </list-item>
          <list-item>
            <p>HIV.</p>
          </list-item>
          <list-item>
            <p>Autoimmune diseases, mainly systemic lupus erythematosus (SLE), Sj&#x000f6;gren syndrome, and adult-onset&#x000a0;Still disease.<xref ref-type="bibr" rid="article-20147.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Lymphoproliferative disorders.</p>
          </list-item>
        </list>
        <p>About 10% of cases have no identifiable disease association; hence, cryoglobulinemia is termed "essential mixed cryoglobulinemia."</p>
        <p><bold>Type III:&#x000a0;</bold>Cryoglobulins in type III cryoglobulinemia are a mixture of polyclonal IgG (all isotypes) and polyclonal IgM. These cases are often secondary to autoimmune disorders and occasionally associated with infections, most commonly HCV.&#x000a0;</p>
      </sec>
      <sec id="article-20147.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Cryoglobulin is normally present in healthy individuals at&#x000a0;low levels.&#x000a0;Experts theorize that these levels indicate the existence of immune complexes actively working to clear this protein by immunoglobulins with RF activity.<xref ref-type="bibr" rid="article-20147.r2">[2]</xref><xref ref-type="bibr" rid="article-20147.r6">[6]</xref></p>
        <p>The prime risk factor for cryoglobulinemia is drug use, as 90% of cases of cryoglobulinemic vasculitis are associated with&#x000a0;HCV infections. The formation of hepatitis C IgG and IgM&#x000a0;RF causes the immune complex formation and complement activation, leading to blood vessel inflammation. In addition, cryoglobulinemia is also associated with monoclonal gammopathies (such as multiple myeloma, Waldenstr&#x000f6;m macroglobulinemia, or MGUS), monoclonal gammopathies of renal significance, and connective tissue diseases (such as&#x000a0;SLE and Sj&#x000f6;gren syndrome).</p>
      </sec>
      <sec id="article-20147.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cryoglobulinemia is a rare condition and is clinically significant in about 1 in 100,000 individuals, with a higher prevalence observed in southern Europe. Cryoglobulins have been identified in several patient populations, specifically 15% to 20% of HIV-infected individuals, 40% to 65% of HCV-infected patients, and&#x000a0;over 90% of HIV/HCV-coinfected individuals.<xref ref-type="bibr" rid="article-20147.r7">[7]</xref><xref ref-type="bibr" rid="article-20147.r8">[8]</xref><xref ref-type="bibr" rid="article-20147.r9">[9]</xref><xref ref-type="bibr" rid="article-20147.r10">[10]</xref><xref ref-type="bibr" rid="article-20147.r11">[11]</xref>&#x000a0;In addition, the condition is also linked to autoimmune diseases, such as SLE and Sj&#x000f6;gren syndrome, as well as hematologic malignancies, such as multiple myeloma and lymphoma.</p>
        <p>Cryoglobulinemia predominantly affects adults, with a higher incidence observed in females than males. Based on the currently available case series, patients with type 1 cryoglobulin account for 5% to 25% of the cases. Geographic variations in prevalence are noted, correlating with the distribution of HCV infection and other associated diseases. Due to its association with various underlying conditions, the epidemiology of cryoglobulinemia reflects a complex interplay between genetic, environmental, and infectious factors.</p>
      </sec>
      <sec id="article-20147.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Chronic immune stimulation and lymphoproliferation lead to increased production of higher levels of mono-, oligo-, or polyclonal immunoglobulins, which subsequently form cryoglobulins.&#x000a0;These cryoglobulins circulate in the blood and can precipitate, forming immune complexes that deposit in small- to medium-sized blood vessels, leading to vascular occlusion and inflammation. The deposition triggers an inflammatory response, causing endothelial cell injury and attracting immune cells such as lymphocytes and macrophages to the site. In addition, the immune complexes activate the complement system, further contributing to inflammation and tissue damage. Organs commonly affected include the skin, kidneys, and peripheral nerves, with clinical manifestations such as purpura, glomerulonephritis, and neuropathy.</p>
      </sec>
      <sec id="article-20147.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Tissue biopsy reveals small-vessel leukocytoclastic vasculitis, indicating inflammation of the blood vessels. Histological findings typically include endothelial cell swelling, fibrinoid necrosis of the vessel walls, and perivascular infiltrates of lymphocytes, macrophages, and neutrophils.</p>
        <p>Hypersensitivity vasculitis or angiitis is evident in 50% of cases, while inflammatory or noninflammatory purpura is present in 15%. Noninflammatory hyaline thrombosis, more common in type I cryoglobulinemia, is observed in 10% of cases.<xref ref-type="bibr" rid="article-20147.r12">[12]</xref>&#x000a0;In cryoglobulinemia, vasculitis is the most common finding, whereas hyperviscosity syndrome is the least common.<xref ref-type="bibr" rid="article-20147.r13">[13]</xref></p>
        <p>Renal complications of cryoglobulinemia occur in up to half of patients with HCV positivity. The most common pattern, seen in up to 90% of cases, is membranoproliferative glomerulonephritis, often referred to as "cryoglobulinemic glomerulonephritis."<xref ref-type="bibr" rid="article-20147.r14">[14]</xref><xref ref-type="bibr" rid="article-20147.r15">[15]</xref>&#x000a0;Common manifestations include endocapillary hypercellularity, mainly composed of monocytes, duplication of the peripheral basement membrane, and the presence of intercapillary pseudothrombi.<xref ref-type="bibr" rid="article-20147.r16">[16]</xref><xref ref-type="bibr" rid="article-20147.r17">[17]</xref><xref ref-type="bibr" rid="article-20147.r18">[18]</xref>&#x000a0;These pseudothrombi, or hyaline thrombi, represent immune complex deposits in the mesangial, subendothelial, and capillary walls or lumens.<xref ref-type="bibr" rid="article-20147.r15">[15]</xref>&#x000a0;Characteristic features include glomerular monocytes or macrophages (CD68+) and low C4 levels. Glomerular necrosis and crescent formation are evident in less than 5% of cases, while mesangial proliferation varies.</p>
      </sec>
      <sec id="article-20147.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A documented history of&#x000a0;various conditions can help identify cryoglobulinemia. Some conditions commonly associated with this disease include clonal hematologic disease (myeloma and MGUS), autoimmune diseases, infections with HBV, HCV, or HIV, skin purpura on lower limbs, skin ulcers under cold conditions, and acute foot or wrist drop suggestive of neuropathy from ischemia.&#x000a0;</p>
        <p>Notable clinical features include arthralgias (44%), purpura (75%), skin ulcers (16%), glomerulonephritis (35%), and peripheral neuropathy (57%). Careful attention is required if these symptoms occur alongside a clonal hematologic disorder.</p>
        <p>
<bold>Clinical Classification of Cryoglobulinemia</bold>
</p>
        <p>The presentation of cryoglobulinemia can vary significantly, with a majority of cases being asymptomatic. Cryoglobulinemia can clinically be classified as mentioned below.</p>
        <p><bold>Type I cryoglobulinemia:&#x000a0;</bold>Type I&#x000a0;presents with vascular symptoms, including ischemia, livedo reticularis (an erythematous, reticulated pattern that appears lace-like and blanches&#x000a0;with pressure), and skin necrosis.<xref ref-type="bibr" rid="article-20147.r19">[19]</xref><xref ref-type="bibr" rid="article-20147.r20">[20]</xref><xref ref-type="bibr" rid="article-20147.r21">[21]</xref><xref ref-type="bibr" rid="article-20147.r22">[22]</xref>&#x000a0;This type most commonly exhibits skin manifestations&#x000a0;with a frequency of approximately 70% to 85%. While exercising caution regarding the diagnosis, prompt treatment of the skin&#x000a0;abnormalities is essential to prevent the development of digital gangrene.</p>
        <p>During initial studies of this specific type of cryoglobulinemia, French researchers&#x000a0;initiated&#x000a0;a nationwide study involving 64 patients with expressed symptoms over 15 years.<xref ref-type="bibr" rid="article-20147.r19">[19]</xref>&#x000a0;All patients exhibited cutaneous associations, often resulting in ulcers and necrosis. Typical findings also included peripheral neuropathy, arthralgia, and arthritis. None of the participants in this study showed any central nervous system (CNS), pulmonary, cardiac, or gastrointestinal symptoms.</p>
        <p><bold>Type II/III (mixed) cryoglobulinemia:&#x000a0;</bold>The presentation of mixed cryoglobulinemia is commonly associated with underlying symptoms such as arthralgia, fatigue, and myalgia. Also, palpable purpura related to vasculitis or sensory changes due to peripheral neuropathy&#x000a0;are common with type II/III.<xref ref-type="bibr" rid="article-20147.r23">[23]</xref>&#x000a0;</p>
        <p>The symptoms usually seen are referred to as "Meltzer triad," consisting of purpura, arthralgias, and weakness. Meltzer triad is detected early in the clinical presentation in approximately 80% of patients.<xref ref-type="bibr" rid="article-20147.r24">[24]</xref>&#x000a0;The most prevailing symptom of mixed cryoglobulinemia is purpura, typically observed on the legs, extending up to the torso and/or upper extremities.<xref ref-type="bibr" rid="article-20147.r21">[21]</xref>&#x000a0;Usual&#x000a0;symptoms persist for approximately 1 to 2 weeks, with intermittent episodes occurring 1 to 2 times per month.</p>
      </sec>
      <sec id="article-20147.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The most predictive measure for cryoglobulinemia is the measurement of cryoglobulin coupled with a low C4 complement level. This combination is typical of cryoglobulinemia syndromes.<xref ref-type="bibr" rid="article-20147.r25">[25]</xref>&#x000a0;</p>
        <p>In the lab detection of cryoglobulins, approximately 10 to 20 mL of blood is collected and prepared at 37 &#x000b0;C without the addition of anticoagulants. The serum is centrifuged and then refrigerated to allow the precipitation of cryoglobulin. Type I cryoglobulinemia presents as a precipitate within 24 hours, with a 3- to 5-day window. Type II/III presents with precipitation approximately 5 to 7 days after initial refrigeration.</p>
        <p>A cryocrit is defined as the percentage of cryoglobulin compared to the total serum volume read from a calibrated sedimentation tube. Although this method is convenient, rapid, and inexpensive, it is also found to be dubious in terms of reproducibility. Generally, the cryocrit in individuals without cryoglobulinemia is close to zero, and a cryocrit greater than 0.5% to 1% or a concentration greater than 50 mcg/mL is significant.<xref ref-type="bibr" rid="article-20147.r25">[25]</xref><xref ref-type="bibr" rid="article-20147.r26">[26]</xref><xref ref-type="bibr" rid="article-20147.r27">[27]</xref>&#x000a0;</p>
        <p>In type II cryoglobinemia, the cryocrit is between 2% and 7%, while type III&#x000a0;demonstrates results around 1% to 3%. Type I cryoglobulinemia, associated with IgM monoclonal gammopathies, tends to have a higher cryocrit than type II; the latter virtually never manifests hyperviscosity.<xref ref-type="bibr" rid="article-20147.r28">[28]</xref>&#x000a0;The strengths of a cryocrit test are few, and its&#x000a0;weaknesses tend to overshadow its clinical utility. Notably,&#x000a0;a decrease in the cryocrit over the treatment time may indicate success.<xref ref-type="bibr" rid="article-20147.r29">[29]</xref>&#x000a0;Although symptoms do not correlate with the cryocrit.<xref ref-type="bibr" rid="article-20147.r28">[28]</xref> The cryocrit (and complement levels) do not reflect disease activity.<xref ref-type="bibr" rid="article-20147.r30">[30]</xref> Only the presence of symptoms should determine the initiation of therapy. Asymptomatic patients, even those with a high cryocrit, are said to require no treatment at all.&#x000a0;</p>
        <p>Another common method of evaluating cryoglobulinemia is immunochemical analysis. Immunofixation is performed on dissolved cryoglobulin by antibodies with specified heavy/light chains. This test allows for the specific categorization of the type after the initial diagnosis. Other lab testing includes urinalysis, complement serum analysis, RF levels, viral serologies, and analysis of acute-phase reactants. In particular cases, specific testing is performed for further evaluation. One such test is the biopsy of organs impacted by the disease, which is used to acquire additional information. Type I cryoglobulinemia is generally seen in the skin, kidney, and bone marrow and is associated with thromboses. Type II/III presents within the skin, kidney, and peripheral nervous system.</p>
        <p>Electromyography (EMG) is another test used in situations where neuromuscular disease is evident. Lastly, imaging studies can be utilized to confirm the presence of cryoglobulinemia. However, it is important not to rely solely on imaging for evaluation; the specified clinical presentation should guide these tests.</p>
        <p>Renal complications of cryoglobulinemia occur in upwards of half of patients with HCV positivity. They typically occur 3 to 5 years after the purpura appears and most commonly take the form of membranoproliferative glomerulonephritis.<xref ref-type="bibr" rid="article-20147.r15">[15]</xref><xref ref-type="bibr" rid="article-20147.r4">[4]</xref> A renal biopsy can provide data on the extent of the disease.</p>
      </sec>
      <sec id="article-20147.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of cryoglobulinemia depends on the underlying primary disorder, severity, and nature of organ involvement. In presentations&#x000a0;of mixed cryoglobulinemia with symptoms, the treatment is directed at the underlying autoimmune or infectious disorders. In the case of essential mixed cryoglobulinemia, the clinical course is more severe, and the recommended treatment is steroids combined with rituximab, with the steroids to be tapered.&#x000a0;In addition, the treatment for cryoglobulinemia focuses on each individual case and includes plasmapheresis and immunosuppression (such as glucocorticoids and rituximab) for patients with rapidly progressing or life-threatening outcomes. The treatment is directed toward the underlying infection or autoimmune disorder. Generally, the treatment is tailored to address the underlying (causal) disease, the presence of hyperviscosity, and any co-occurring organ involvement or damage.</p>
        <p>HCV infections most commonly cause mixed cryoglobulinemia. The connection between infection and autoimmune or lymphoproliferative disorders is common. The general onset of this disease is slow-paced, but in&#x000a0;some situations, rapid progression can occur. In recent years, with the advent of direct antiviral therapy, there has been a change in the treatment approach.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;HCV-positive patients with cryoglobulinemia are now recommended to receive initial therapy with pan-genotypic antiviral regimens (such as&#x000a0;sofosbuvir or velpatasvir and glecaprevir or pibrentasvir). HCV genotyping and subtyping should continue, but initial treatment is still important.</p>
        <p>Studies have demonstrated a response rate with minimal viral counts in almost 100% of patients, although about 13% experience a relapse.<xref ref-type="bibr" rid="article-20147.r21">[21]</xref> The administration of antivirals in HCV-B-cell clonalities is necessary to eliminate the viral threat, especially considering the immunosuppressives used to obliterate the clone. Direct antiviral agents have a better tolerability and safety profile than interferon (IFN), with the latter exhibiting a superior anti-lymphoma effect.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref><xref ref-type="bibr" rid="article-20147.r31">[31]</xref> There were no significant differences in overall survival or progression-free survival between the 2 treatments.</p>
        <p>Cyclophosphamide has been utilized alongside apheresis to address high cryocrit levels and prevent a post-apheresis rebound in cryoglobulin synthesis. However, its usage has diminished due to the rise of B-cell&#x02013;depleting monoclonal antibodies such as rituximab. When using rituximab, close monitoring of patients with latent HBV infection is essential, and appropriate prophylaxis should be provided. Monitoring HBV DNA or hepatitis B surface antigen (HBsAg) is also recommended. Low-dose monoclonal antibodies or concurrent administration of an antiviral regimen may offer additional benefits.&#x000a0;</p>
        <p>
<bold>Classification Based on&#x000a0;Disease Severity</bold>
</p>
        <p>The apparent severity of the disease guides healthcare professionals on how best to treat the patient. Although there is no established outline for severity designations, the descriptions below are used for guidance.</p>
        <p><bold>Mild disease:&#x000a0;</bold>Healthcare professionals typically do not prescribe immunosuppressive treatment in cases classified as mild. Instead, the focus lies on treating the underlying disease.</p>
        <p>Manifestations of mild disease often include a petechial rash without lesions, arthralgia without apparent organ damage, and mild sensory neuropathy.</p>
        <p><bold>Moderate-to-severe disease:&#x000a0;</bold>In&#x000a0;this clinical scenario, immunosuppressive treatment may not be necessary, as the primary focus remains on treating the underlying (causative) disease.</p>
        <p>In this classification, the presentation includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Progressive neuropathy</p>
          </list-item>
          <list-item>
            <p>Pulmonary vasculitis</p>
          </list-item>
          <list-item>
            <p>CNS vasculitis presenting as a stroke or cognitive impairment</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal vasculitis associated with bleeding and abdominal pain</p>
          </list-item>
          <list-item>
            <p>Digital ischemia</p>
          </list-item>
        </list>
        <p>The aforementioned clinical indicators do not comprise a complete list of manifestations.</p>
        <p>A comprehensive treatment plan for managing mixed cryoglobulinemia typically involves pain management, wound care, and preventive measures against infections. Appropriate prophylaxis is crucial, particularly for patients undergoing steroid or immunosuppressive therapy. The treatment strategy should be tailored to address the disease's existing etiology.</p>
        <p>In moderate-to-severe cases, the specialized focus is to address the primary symptoms with immunosuppressive therapy. Typically, immunosuppressive therapy is initiated until a steady state is achieved, followed by the devised regimen. For patients with HIV or HBV, antiviral therapy should be initiated before or alongside immunosuppressive treatment. A combination of high-dose glucocorticoids and rituximab is recommended as an initial treatment approach for moderate to severe cryoglobulinemia.</p>
        <p>Rituximab has demonstrated effectiveness in treating cryoglobulinemia by improving vasculitis, reducing RF levels, normalizing C4 complement levels, and depleting B-cell clones in both bone marrow and peripheral blood.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref><xref ref-type="bibr" rid="article-20147.r32">[32]</xref> However, its use comes with potential toxicities, such as life-threatening vasculitis flares, serum sickness syndrome, and exacerbation of HCV viremia. Maintenance therapy with rituximab is recommended for cases of severe, life-threatening vasculitis.<xref ref-type="bibr" rid="article-20147.r33">[33]</xref></p>
        <p>Cyclophosphamide, combined with apheresis, has effectively addressed high cryocrit levels, which contribute to hyperviscosity syndrome in cryoglobulinemia, and has prevented post-apheresis rebound in cryoglobulin synthesis.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;Cyclophosphamide can also be administered concurrently with steroids. However, the role of steroids appears to be limited, as they are not typically used in maintenance therapy. Cyclophosphamide and rituximab are known to have steroid-sparing effects.</p>
        <p>Presently, apheresis is considered a second-line treatment option for cryoglobulinemic vasculitis.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;However, as outlined below, apheresis&#x000a0;is crucial&#x000a0;in severe conditions, which include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperviscosity syndrome (especially with a cryocrit exceeds 10%)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Skin ulcers caused by cutaneous vasculitis</p>
          </list-item>
          <list-item>
            <p>Life-threatening, multiorgan cryoglobulinemic vasculitis</p>
          </list-item>
          <list-item>
            <p>Rapidly progressing renal failure</p>
          </list-item>
          <list-item>
            <p>Refractory neuropathy</p>
          </list-item>
        </list>
        <p>For apheresis, the recommended course typically involves daily exchanges approximately 3 times per week over a couple of weeks. Double-filtration plasmapheresis has also successfully treated cryoglobulinemic vasculitis, leading to a faster and more sustained response.<xref ref-type="bibr" rid="article-20147.r34">[34]</xref> Despite its effectiveness, therapeutic apheresis now assumes a more&#x000a0;subordinate&#x000a0;role, albeit with a favorable safety profile.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;This rapidly reduces cryoglobulins and viral particles, primarily addressing hyperviscosity concerns. Cyclophosphamide or steroids are often administered to counteract any post-apheresis rebound in cryoglobulins. Notably, apheresis usage in cryoglobulinemic patients with renal involvement has shown a high response rate of 78%, with most patients experiencing long-term recovery.<xref ref-type="bibr" rid="article-20147.r35">[35]</xref></p>
        <p>Steroids and cyclophosphamide are frequently administered alongside apheresis to mitigate the risk of a post-apheresis rebound in cryoglobulin production. Cyclophosphamide, along with rituximab, can also serve as steroid-sparing agents. However, their use is approached cautiously due to the associated risk of infection. Steroids, on the other hand, are believed to have no maintenance role in the treatment of cryoglobulinemic vasculitis.&#x000a0;</p>
        <p>Patients undergoing immunosuppressive treatments for cryoglobulinemia necessitate close monitoring, the extent of which hinges on the severity of the condition. During physical examinations, particular attention should be paid to skin involvement and the presence of digital ischemia.</p>
        <p>In cases involving kidney treatment, close monitoring of blood pressure, creatinine levels, complement levels, RF levels, and urinalysis is necessary. Patients with progressive glomerulonephritis should undergo weekly observation, while those with conditions exhibiting slower disease progression can be evaluated monthly. The extent of organ involvement significantly influences the prescribed regimen and overall prognosis. Individuals with intestinal vasculitis or acute gastrointestinal or pulmonary hemorrhage typically face poor outcomes.</p>
        <p>Patients with cryoglobulinemic vasculitis are considered "immunologically frail."<xref ref-type="bibr" rid="article-20147.r18">[18]</xref><xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;Therefore, it is strongly recommended that those patients receive vaccinations against influenza, pneumococci, varicella zoster, and COVID-19. Vaccination should ideally occur before administering steroids or immunosuppressive drugs. If patients are already undergoing treatment with rituximab or other immunosuppressives, vaccination should be delayed for at least 6 months after the last infusion or 4 weeks before the next infusion to optimize response. Notably, COVID-19 vaccinations have been associated with relapses of cryoglobulinemic vasculitis, sometimes leading to renal damage.<xref ref-type="bibr" rid="article-20147.r16">[16]</xref><xref ref-type="bibr" rid="article-20147.r17">[17]</xref><xref ref-type="bibr" rid="article-20147.r18">[18]</xref> The risk of a vasculitis flare triggered by the vaccine is notable, yet the benefits of vaccination are deemed to outweigh these risks.</p>
      </sec>
      <sec id="article-20147.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Cryoglobulinemia must be diagnosed carefully, as its clinical presentation is similar to other vasculitides affecting small- or medium-sized vessels. The differential diagnoses of cryoglobulinemia include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (such as granulomatosis with polyangiitis [Wegener], eosinophilic granulomatosis with polyangiitis [Churg-Strauss], and microscopic polyangiitis).</p>
          </list-item>
          <list-item>
            <p>IgA vasculitis (Henoch-Sch&#x000f6;nlein purpura).</p>
          </list-item>
          <list-item>
            <p>Cutaneous small-vessel vasculitis.</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity vasculitis.</p>
          </list-item>
          <list-item>
            <p>Vasculitis associated with a connective tissue disorder (such as&#x000a0;SLE, rheumatoid arthritis, and Sj&#x000f6;gren syndrome).</p>
          </list-item>
        </list>
        <p>Other thrombotic and embolic disorders, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, should also be considered in the differential diagnosis. Additionally, patients affected by chronic HCV infection may develop arthralgias and membranoproliferative nephritis even without cryoglobulinemia. Therefore, further testing is necessary to reach a definitive diagnosis.</p>
      </sec>
      <sec id="article-20147.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>When assessing the prognosis of cryoglobulinemia, the patient's underlying condition must be considered to determine the disease's extent accurately. Specifically, when considering type 1 cryoglobulinemia, hematologic diseases are often a preexisting condition.<xref ref-type="bibr" rid="article-20147.r22">[22]</xref>&#x000a0;Studies have shown that the presence of cryoglobulins in the blood does not indicate a higher mortality rate.</p>
        <p>Survival rates with cryoglobulinemia are 70% after 10 years of evident symptoms and approximately 50% 10 years after diagnosis. The prognosis largely depends on comorbidities and their severity, as well as the effectiveness of treatment.<xref ref-type="bibr" rid="article-20147.r36">[36]</xref>&#x000a0;Recent trials with the CD-20 antibody rituximab have shown some beneficial results, and its use is being favored.<xref ref-type="bibr" rid="article-20147.r37">[37]</xref></p>
        <p>HCV-related cryoglobulinemia vasculitis is a significant disease with an approximate 5-year mortality rate of 25%.<xref ref-type="bibr" rid="article-20147.r1">[1]</xref><xref ref-type="bibr" rid="article-20147.r38">[38]</xref>&#x000a0;Prognosis, aside from liver fibrosis, usually depends on the status of the kidneys, CNS, heart, and gastrointestinal tract. The vascularity associated with these organs is affected and contributes heavily to the prognosis. Renal failure is shown to be higher in those with&#x000a0;HCV compared to mixed cryoglobulinemia.</p>
      </sec>
      <sec id="article-20147.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with cryoglobulinemia typically affect the outcomes of prognoses. Studies have indicated that complications usually result in lower chances of survival for a patient. Common complications include renal failure and the underlying development of a lymphoproliferative disorder.</p>
        <p>HCV-related indolent non-Hodgkin lymphoma has been successfully treated with direct antiviral therapy alone.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;However, for higher-grade lymphomas, the use of antivirals during the peri-chemotherapy period remains an open decision.</p>
        <p>Renal complications of cryoglobulinemia occur in upward of half of the patients with HCV positivity, typically 3 to 5 years after the onset of purpura, and most commonly manifest as membranoproliferative glomerulonephritis.<xref ref-type="bibr" rid="article-20147.r4">[4]</xref>&#x000a0;A renal biopsy can provide data on the extent of the disease, and the overall prognosis is poor. Indolent renal effects can be addressed with antivirals, while severe effects warrant immunosuppressives supplemented by steroids and apheresis. Even if a sustained virologic response is achieved, organ recovery often lags.&#x000a0;</p>
      </sec>
      <sec id="article-20147.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients with cryoglobulinemia often require multidisciplinary consultations to address the underlying causes, manage systemic symptoms, and monitor disease progression. These consultations may include hematology, infectious diseases, nephrology, neurology, and rheumatology.</p>
      </sec>
      <sec id="article-20147.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education are crucial components in managing cryoglobulinemia, aiming to prevent disease exacerbations and improve overall outcomes. Patient education should emphasize the importance of regular medical follow-ups to monitor disease progression, adhere to prescribed treatments, and recognize early signs of disease flares or complications. Early medical therapy is essential to avoid potential organ damage.</p>
        <p>Patients should be informed about lifestyle modifications, such as avoiding exposure to cold temperatures and trauma and minimizing alcohol consumption, which can exacerbate symptoms. Patients with mild disease, primarily presenting as arthralgias and fatigue, can benefit from nonsteroidal anti-inflammatory drugs to reduce symptoms acutely.</p>
        <p>Additionally, patients should be educated about the potential complications of cryoglobulinemia, such as renal involvement and peripheral neuropathy, and encouraged to seek prompt medical attention if new symptoms arise. Empowering patients with knowledge about their condition and strategies for self-management can help optimize treatment outcomes and enhance overall quality of life.</p>
      </sec>
      <sec id="article-20147.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A nuanced approach is essential in navigating the complexities of cryoglobulinemia. Clinical pearls can aid in the management of this challenging condition and include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>In managing cryoglobulinemia, healthcare professionals should always investigate and address potential underlying causes, such as HCV infection, autoimmune diseases, or hematologic malignancies, as effective management often relies on treating the primary condition.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should educate patients on recognizing symptoms of cryoglobulinemia, such as purpura, arthralgia, neuropathy, and renal impairment, to facilitate early intervention and prevent disease progression.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should emphasize the importance of avoiding cold exposure, as cryoglobulin precipitation and symptom exacerbation can occur in response to low temperatures.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should perform a thorough evaluation, including clinical examination, laboratory tests for cryoglobulins, and imaging studies, to assess disease severity, monitor progression, and identify associated organ involvement.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should collaborate with specialists from various fields, including rheumatology, hematology, nephrology, and infectious diseases, to provide comprehensive care and address the diverse manifestations of cryoglobulinemia.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals may consider using immunosuppressive agents, such as corticosteroids, rituximab, or other immunomodulatory drugs, combined with antiviral therapy for HCV, to manage systemic symptoms and prevent disease flares.</p>
          </list-item>
          <list-item>
            <p>Healthcare providers should monitor renal function regularly, as cryoglobulinemia can lead to glomerulonephritis and renal impairment, necessitating early intervention to prevent irreversible kidney damage.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should manage peripheral neuropathy symptoms with pain relief medications, physical therapy, and supportive measures to improve patient quality of life and functional outcomes.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should provide comprehensive patient education on disease management, including medication adherence, lifestyle modifications, and the importance of regular follow-up care. This approach aims to optimize treatment outcomes and minimize disease complications.</p>
          </list-item>
          <list-item>
            <p>Healthcare professionals should implement a long-term monitoring plan to track disease progression, assess treatment response, and detect any potential complications or disease flares early. This approach allows for timely intervention and adjustment of management strategies.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20147.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the comprehensive management of cryoglobulinemia, an interprofessional healthcare team comprising physicians, advanced care practitioners, nurses, pharmacists, and other healthcare professionals is critical in delivering patient-centered care and optimizing outcomes while ensuring patient safety and effective team performance. Each member of the healthcare team should possess specialized skills relevant to their respective roles in managing cryoglobulinemia.</p>
        <p>Physicians and advanced practitioners need expertise in diagnosing and treating the condition, interpreting laboratory results, and coordinating comprehensive care plans. Nurses require proficiency in patient assessment, administering medications, monitoring for adverse reactions, and providing patient education. Pharmacists contribute their expertise in medication management, ensuring appropriate dosing, monitoring for drug interactions, and counseling patients on medication adherence and potential&#x000a0;adverse effects. Effective delegation and clear communication of responsibilities within the team are essential for coordinated care delivery.&#x000a0;</p>
        <p>Collaborative strategy development is essential for establishing standardized protocols, treatment guidelines, and care pathways for managing cryoglobulinemia.&#x000a0;The involvement of specialists such as rheumatologists, hematologists, nephrologists, and infectious disease specialists allows for tailored treatment strategies and holistic management of associated conditions. Through interdisciplinary communication and coordination, the interprofessional team can address the diverse needs of patients with cryoglobulinemia, optimize treatment outcomes, and enhance the overall quality of patient care.</p>
      </sec>
      <sec id="article-20147.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20147&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20147">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/cryoglobulinemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20147">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20147/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20147">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20147.s18">
        <title>References</title>
        <ref id="article-20147.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>The cryoglobulinaemias.</article-title>
            <source>Lancet</source>
            <year>2012</year>
            <month>Jan</month>
            <day>28</day>
            <volume>379</volume>
            <issue>9813</issue>
            <fpage>348</fpage>
            <page-range>348-60</page-range>
            <pub-id pub-id-type="pmid">21868085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brouet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Clauvel</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Danon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seligmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Biologic and clinical significance of cryoglobulins. A report of 86 cases.</article-title>
            <source>Am J Med</source>
            <year>1974</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>775</fpage>
            <page-range>775-88</page-range>
            <pub-id pub-id-type="pmid">4216269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trejo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Carrasco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yag&#x000fc;e</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de la Red</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Font</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ingelmo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>252</fpage>
            <page-range>252-62</page-range>
            <pub-id pub-id-type="pmid">11470986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dammacco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lauletta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.</article-title>
            <source>Clin Exp Med</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-272</page-range>
            <pub-id pub-id-type="pmid">35348938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakagawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia vasculitis associated with adult-onset Still's disease.</article-title>
            <source>Clin Case Rep</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>e8632</fpage>
            <pub-id pub-id-type="pmid">38455857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagnino</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Reappraisal of the clinical expression of mixed cryoglobulinemia.</article-title>
            <source>Springer Semin Immunopathol</source>
            <year>1988</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-19</page-range>
            <pub-id pub-id-type="pmid">3046019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MOHR</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Pathological anatomy of the effects of embryonal heart extract (corhormon).</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>1952</year>
            <month>Oct</month>
            <day>17</day>
            <volume>77</volume>
            <issue>42</issue>
            <fpage>1287</fpage>
            <page-range>1287-90</page-range>
            <pub-id pub-id-type="pmid">12988806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Carrasco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trejo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yag&#x000fc;e</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sis&#x000f3;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de La Red</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Font</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ingelmo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>366</fpage>
            <page-range>366-73</page-range>
            <pub-id pub-id-type="pmid">11303309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cervera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yag&#x000fc;e</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Carrasco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trejo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morl&#x000e0;</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Font</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ingelmo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia in primary Sj&#x000f6;gren's syndrome: prevalence and clinical characteristics in a series of 115 patients.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <page-range>200-5</page-range>
            <pub-id pub-id-type="pmid">9872481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cicardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cesana</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Del Ninno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pappalardo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agostoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C.</article-title>
            <source>J Viral Hepat</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-43</page-range>
            <pub-id pub-id-type="pmid">10760044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jara</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Calvo-Alen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brito-Zer&#x000f3;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Forns</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Tapias</surname>
                <given-names>JM</given-names>
              </name>
              <collab>HISPAMEC Study Group</collab>
            </person-group>
            <article-title>Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry).</article-title>
            <source>J Rheumatol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>1442</fpage>
            <page-range>1442-8</page-range>
            <pub-id pub-id-type="pmid">19369460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pittelkow</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>1 Pt 1</issue>
            <fpage>21</fpage>
            <page-range>21-7</page-range>
            <pub-id pub-id-type="pmid">1880249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Retamozo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quartuccio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ramos-Casals</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia.</article-title>
            <source>Med Clin (Barc)</source>
            <year>2022</year>
            <month>May</month>
            <day>27</day>
            <volume>158</volume>
            <issue>10</issue>
            <fpage>478</fpage>
            <page-range>478-487</page-range>
            <pub-id pub-id-type="pmid">35216803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hopfer</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Renal Disease in Cryoglobulinemia.</article-title>
            <source>Glomerular Dis</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-104</page-range>
            <pub-id pub-id-type="pmid">36751424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rui</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemic vasculitis and glomerulonephritis: concerns in clinical practice.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2019</year>
            <month>Jul</month>
            <day>20</day>
            <volume>132</volume>
            <issue>14</issue>
            <fpage>1723</fpage>
            <page-range>1723-1732</page-range>
            <pub-id pub-id-type="pmid">31283654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vornicu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berechet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fr&#x00103;&#x0021b;il&#x00103;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Obri&#x0015f;c&#x00103;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jurcu&#x00163;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Relapse of cryoglobulinemic vasculitis with new-onset severe renal involvement in two patients following mRNA COVID-19 vaccination: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Jun</month>
            <day>10</day>
            <volume>101</volume>
            <issue>23</issue>
            <fpage>e29431</fpage>
            <pub-id pub-id-type="pmid">35687780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bourke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ardakani</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine.</article-title>
            <source>BMJ Case Rep</source>
            <year>2022</year>
            <month>Jul</month>
            <day>18</day>
            <volume>15</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">35850789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Visentini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gragnani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Urraro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palladino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petraccia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>La Gualana</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lorini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Madia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stefanini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Basili</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fiorilli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zignego</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Casato</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>441</fpage>
            <page-range>441-443</page-range>
            <pub-id pub-id-type="pmid">34819272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Le Guenno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Benarous</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lacraz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Diot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>de Saint-Martin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cath&#x000e9;bras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Modiano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>L&#x000e9;ger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Senet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Plaisier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saadoun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-68</page-range>
            <pub-id pub-id-type="pmid">23429354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jahn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aucouturier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galicier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Asli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Malphettes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szalat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brouet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lipsker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fermand</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases.</article-title>
            <source>Br J Haematol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>168</volume>
            <issue>5</issue>
            <fpage>671</fpage>
            <page-range>671-8</page-range>
            <pub-id pub-id-type="pmid">25363150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muchtar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Magen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>How I treat cryoglobulinemia.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Jan</month>
            <day>19</day>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-298</page-range>
            <pub-id pub-id-type="pmid">27799164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sidana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lacy</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buadi</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Hayman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Dingli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gonsalves</surname>
                <given-names>WI</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hwa</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fonder</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zeldenrust</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lust</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia.</article-title>
            <source>Am J Hematol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>92</volume>
            <issue>7</issue>
            <fpage>668</fpage>
            <page-range>668-673</page-range>
            <pub-id pub-id-type="pmid">28370486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Della Rossa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trevisani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>1998</year>
            <season>Fall</season>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-64</page-range>
            <pub-id pub-id-type="pmid">9773252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toriu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oguro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sumida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suwabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hiramatsu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yamanouchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Takaichi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ubara</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Renal-limited Cryoglobulinemic Vasculitis: Two Case Reports.</article-title>
            <source>Intern Med</source>
            <year>2018</year>
            <volume>57</volume>
            <issue>13</issue>
            <fpage>1879</fpage>
            <page-range>1879-1886</page-range>
            <pub-id pub-id-type="pmid">29962417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gorevic</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kassab</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Levo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.</article-title>
            <source>Am J Med</source>
            <year>1980</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <page-range>287-308</page-range>
            <pub-id pub-id-type="pmid">6996482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trendelenburg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schifferli</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulins are not essential.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">9536813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Della Rossa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tavoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Ascanio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Catarsi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bencivelli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Salvadori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Migliorini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-70</page-range>
            <pub-id pub-id-type="pmid">20337547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khwaja</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Sa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minnema</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kersten</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>IgM monoclonal gammopathies of clinical significance: diagnosis and management.</article-title>
            <source>Haematologica</source>
            <year>2022</year>
            <month>Sep</month>
            <day>01</day>
            <volume>107</volume>
            <issue>9</issue>
            <fpage>2037</fpage>
            <page-range>2037-2050</page-range>
            <pub-id pub-id-type="pmid">35770530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yerrabothala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Successful use of cryocrit for monitoring response to therapeutic plasma exchange in type 1 cryoglobulinemia.</article-title>
            <source>J Clin Apher</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-4</page-range>
            <pub-id pub-id-type="pmid">26194475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sargur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Egner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulin evaluation: best practice?</article-title>
            <source>Ann Clin Biochem</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>Pt 1</issue>
            <fpage>8</fpage>
            <page-range>8-16</page-range>
            <pub-id pub-id-type="pmid">20040797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Pao</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>823160</fpage>
            <pub-id pub-id-type="pmid">35371039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sagnelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pisaturo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sagnelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Rituximab-based treatment, HCV replication, and hepatic flares.</article-title>
            <source>Clin Dev Immunol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>945950</fpage>
            <pub-id pub-id-type="pmid">22919406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quartuccio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bortoluzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scir&#x000e8;</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Marangoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Del Frate</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Treppo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Castelnovo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saccardo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Candela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fraticelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazzaro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Renoldi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scaini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Visentini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarpato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giuggioli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mascia</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Sebastiani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zignego</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lauletta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fiorilli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pietrogrande</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pioltelli</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>De Vita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC).</article-title>
            <source>Clin Rheumatol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>359</fpage>
            <page-range>359-370</page-range>
            <pub-id pub-id-type="pmid">36169798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naciri Bennani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Banza</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Terrec</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jouve</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Motte</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malvezzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rostaing</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review.</article-title>
            <source>Ther Apher Dial</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>159</fpage>
            <page-range>159-169</page-range>
            <pub-id pub-id-type="pmid">35583180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krisanapan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tangpanithandee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thongprayoon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Therapeutic Apheresis for Cryoglobulinemic Vasculitis Patients with Renal Involvement: A Systematic Review.</article-title>
            <source>Blood Purif</source>
            <year>2024</year>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">37852193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferri</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Mixed cryoglobulinemia.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2008</year>
            <month>Sep</month>
            <day>16</day>
            <volume>3</volume>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">18796155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mascia</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemic vasculitis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-63</page-range>
            <pub-id pub-id-type="pmid">16344620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20147.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Comarmond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Domont</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Savey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saadoun</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cryoglobulinemia Vasculitis.</article-title>
            <source>Am J Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>128</volume>
            <issue>9</issue>
            <fpage>950</fpage>
            <page-range>950-5</page-range>
            <pub-id pub-id-type="pmid">25837517</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
